摘要
目的:评价依达拉奉注射液治疗急性脑梗死(ACI)的有效性和安全性。方法:ACI患者共71例,随机分为治疗组36例,对照组35例。治疗组给予依达拉奉注射液30mg静脉滴注,2次/d,共14d,同时给予低分子右旋糖酐、阿司匹林作为基础治疗;对照组仅给予基础治疗。治疗前、治疗后14d和21d,对患者进行欧洲卒中评分(ESS)、日常生活活动能力(ADL)评定和常规检查,通过增分率判断疗效,同时记录不良反应。结果:治疗组14d和21d评定ESS的有效率分别为77.8%和83.3%,对照组为51.4%和57.1%;14d和21d评定ADL的有效率治疗组为80.6%和88.9%,对照组为57.1%和65.7%;治疗组无明显不良反应。结论:依达拉奉治疗ACI安全有效。
OBJECTIVE To evaluate the efficacy and safety of edaravone in adults with ACI. METHODS Seventy - one patients with ACI were randomly divided into treatment group （ n = 36 ） and control group （ n = 35 ）. Edaravone was infused at a dose of 30mg, twice a day, for 14 days. Meanwhile, Dextran 40 and Amino Acids Injection and Aspirin were taken as basic treatment. The control group was only treated with basic treatment. Before treatment and at 14th, 21th day after treatment, the neurological deficits and activities of daily living （ADL） were evaluated using European Stroke Scale （ESS） and Barthel Index respectively, all the patients were scored by the increase rate and ADR were recorded. RESULTS At 14th, 21th day after treatment, total efficacy of ESS was 77.8% and 83.3% in the treatment group, 51：4% and 57.1% in the control group. Total efficacy of ADL was 80. 6% and 88.9% in the treatment group, 57.1% and 65.7% in the control group. No significant incidences of adverse events were reported in the treatment. CONCLUSION Edaravone is a new effective and safe neuroprotective agent for treating ACI.
出处
《天津药学》
2008年第2期31-32,共2页
Tianjin Pharmacy
关键词
依达拉奉
急性脑梗死
自由基清除剂
edaravone, acute cerebral infarction, free radical scavenger
